Profile data is unavailable for this security.
About the company
Medios AG, formerly Crevalis Capital AG, is a Germany-based company offering solutions in pharma industry. The Company covers relevant aspects of supply chain like from pharmaceutical supply and manufacture of patient-specific therapies, including blistering and others. It operates in two segments Pharmaceutical supply which focuses on pharmaceutical wholesale with finished specialty pharma (high-priced drugs for rare and chronic diseases) medications including oncology, neurology, autoimmunology, ophthalmology, infectiology, hemophilia along with offering finished medicinal products; Patient-specific therapies focusing on pharmaceutical manufacturing of patient-specific preparations such as Cytostatic infusions, Antibody therapies, Virostatic and antibiotic medications, Parenteral nutrition solutions, Investigational medicinal products are among others. Its products and services include Patient health & protection and procedures & processes for patient care and digitalization of data.
- Revenue in EUR (TTM)2.01bn
- Net income in EUR22.03m
- Incorporated1999
- Employees999.00
- LocationMedios AGHeidestrasse 9BERLIN 10557GermanyDEU
- Phone+49 30 232566800
- Fax+49 30 232566801
- Websitehttps://medios.group/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ginwa Enterprise Group Inc | 68.60m | 9.76m | 400.07m | 588.00 | 39.86 | 2.03 | -- | 5.83 | 0.2157 | 0.2157 | 1.54 | 4.24 | 0.2885 | 4.56 | 4.97 | 936,120.60 | 4.04 | 0.839 | 4.86 | 0.9762 | 76.30 | 75.14 | 14.00 | 2.83 | 1.84 | -- | 0.0561 | 52.12 | 3.55 | -4.95 | 273.96 | 23.56 | 28.32 | 0.00 |
| Eton Pharmaceuticals Inc | 60.44m | -5.74m | 404.10m | 31.00 | -- | 20.33 | -- | 6.69 | -0.2491 | -0.2491 | 2.63 | 0.8624 | 1.00 | 3.64 | 7.53 | 2,268,258.00 | -9.52 | -27.81 | -17.48 | -37.96 | 51.36 | 68.16 | -9.50 | -38.41 | 1.25 | 0.2114 | 0.5677 | -- | 23.29 | 109.83 | -308.44 | -- | 40.24 | -- |
| Nxera Pharma Co Ltd | 162.09m | -68.58m | 410.61m | 374.00 | -- | 1.23 | -- | 2.53 | -138.60 | -138.60 | 328.05 | 674.04 | 0.2069 | 0.8144 | 4.11 | -- | -8.75 | -3.79 | -9.90 | -4.16 | 72.32 | 80.12 | -42.31 | -22.17 | 1.90 | -1.30 | 0.4847 | -- | 2.71 | 27.35 | -158.99 | -- | 42.87 | -- |
| Medios AG | 2.01bn | 22.03m | 412.68m | 999.00 | 18.57 | 0.7653 | 6.88 | 0.2051 | 0.8714 | 0.8714 | 78.98 | 21.14 | 2.17 | 21.52 | 12.29 | 2,006,511.00 | 2.38 | 2.59 | 3.37 | 3.09 | 9.66 | 6.53 | 1.09 | 0.8621 | 1.31 | 4.76 | 0.2765 | 0.00 | 5.51 | 29.51 | -33.29 | 5.15 | 24.73 | -- |
| Blau Farmaceutica SA | 290.66m | 52.01m | 414.04m | 1.90k | 7.83 | 1.07 | 6.63 | 1.42 | 1.39 | 1.39 | 7.59 | 10.17 | 0.5156 | 1.68 | 3.45 | -- | 9.22 | 12.47 | 11.00 | 14.84 | 40.23 | 42.91 | 17.89 | 19.76 | 1.85 | 41.28 | 0.1893 | 16.42 | 27.81 | 12.41 | -13.05 | 1.64 | 24.25 | -- |
| Invivyd Inc | 43.01m | -51.46m | 414.49m | 99.00 | -- | 3.94 | -- | 9.64 | -0.4736 | -0.4736 | 0.3778 | 0.4341 | 0.3324 | -- | 5.56 | 505,444.40 | -39.76 | -- | -67.24 | -- | 93.34 | -- | -119.63 | -- | -- | -- | 0.00 | -- | -- | -- | 14.46 | -- | -- | -- |
| Oncolys Biopharma Inc | 156.24k | -11.26m | 416.03m | 35.00 | -- | 18.99 | -- | 2,662.79 | -80.66 | -80.66 | 1.11 | 136.64 | 0.0074 | 0.00 | 0.1004 | -- | -53.08 | -53.26 | -58.54 | -60.19 | 0.00 | -- | -7,209.58 | -484.93 | 9.54 | -424.60 | 0.0741 | -- | -9.04 | -38.10 | -22.16 | -- | 2.22 | -- |
| JCR Pharmaceuticals Co Ltd | 205.49m | -13.35m | 423.04m | 987.00 | -- | 1.57 | 166.22 | 2.06 | -19.98 | -19.98 | 307.86 | 379.76 | 0.3432 | 0.4534 | 2.50 | 38,039,510.00 | -2.21 | 5.86 | -3.77 | 9.33 | 70.45 | 73.83 | -6.45 | 13.60 | 0.668 | -- | 0.5295 | 45.13 | -22.86 | 5.94 | -186.42 | -- | 15.37 | 20.11 |
| Shanghai Fudan Forward S&T Co Ltd | 82.41m | -14.83m | 425.02m | 1.41k | -- | 5.48 | -- | 5.16 | -0.1744 | -0.1744 | 0.9721 | 0.9158 | 0.4268 | 0.8015 | 9.29 | 467,663.00 | -7.83 | -3.33 | -14.36 | -5.82 | 32.05 | 39.99 | -18.35 | -7.67 | 0.4787 | -12.63 | 0.4378 | -- | -5.05 | -14.35 | -509.42 | -- | -18.59 | -- |
| Holder | Shares | % Held |
|---|---|---|
| Janus Henderson Investors UK Ltd.as of 17 Oct 2025 | 1.63m | 6.39% |
| Axxion SA (Luxembourg)as of 01 Jan 2026 | 1.55m | 6.09% |
| SEB Investment Management AB (Denmark)as of 02 Jan 2025 | 1.20m | 4.70% |
| Paladin Asset Management Investmentaktiengesellschaft TGVas of 01 Jan 2026 | 613.33k | 2.41% |
| Discover Capital GmbHas of 31 Oct 2025 | 575.00k | 2.25% |
| Cr�dit Mutuel Asset Management SAas of 31 Dec 2024 | 450.00k | 1.76% |
| Norges Bank Investment Managementas of 30 Jun 2025 | 366.50k | 1.44% |
| HC Capital Advisors GmbHas of 31 Oct 2025 | 346.70k | 1.36% |
| Kreissparkasse Biberachas of 28 Nov 2025 | 315.00k | 1.24% |
| GS&P Kapitalanlagegesellschaft SAas of 30 Jun 2025 | 310.00k | 1.22% |
